Sonidegib (INN), also known as LDE225 and marketed as Odomzo, is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) being developed as an anticancer agent by Novartis. It was approved by the FDA for treating basal-cell carcinoma in July 2015 and is awaiting approval in the EU. In the EU, the agent has received positive opinion from the CHMP for approval...Wikipedia

Manufacturer's Website: Odomzo                                                                                                                       Average retail cost: $12,109/30 caps

Vismodegib (trade name Erivedge) is a drug for the treatment of basal-cell carcinoma (BCC). The approval of vismodegib on January 30, 2012, represents the first Hedgehog signaling pathway targeting agent to gain U.S. Food and Drug Administration (FDA) approval...Wikipedia

Manufacturer's Website: Erivedge                                                                                                                         Average retail cost: $19,830/28 caps